# Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

> **NCT07509151** · PHASE3 · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 420 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

## Interventions

- **DRUG:** Surovatamig

## Key facts

- **NCT ID:** NCT07509151
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-08
- **Primary completion:** 2032-11-29
- **Final completion:** 2033-08-29
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07509151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07509151, "Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07509151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*